Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04727242 · ClinicalTrials.gov registry record · Phase 2
CytoreductiveSurgery & HIPEC w/Gemcitabine+Chemotherapy w/Dacarbazine in Uterine Leiomyosarcoma
A Phase 2 study of Uterine Leiomyosarcoma and LMS - Leiomyosarcoma, sponsored by Stanford University.
- Active
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
- 1
- Study location
NCT04727242: Active Phase 2 study of Uterine Leiomyosarcoma and LMS - Leiomyosarcoma, sponsored by Stanford University.
NCT04727242 is a Phase 2 study of Uterine Leiomyosarcoma and LMS - Leiomyosarcoma that is active but no longer recruiting, run by Stanford University. The registered enrollment target is 17 participants, below the 44-participant average among 3 other Uterine Leiomyosarcoma trials with a reported enrollment target (61% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04727242, a Phase 2 study of Uterine Leiomyosarcoma and LMS - Leiomyosarcoma, is active but no longer recruiting, sponsored by Stanford University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to find out if giving a dose of heated chemotherapy in the abdomen immediately after surgery that is done to remove uterine leiomyosarcoma type of cancer will help lower the risk of the cancer coming back in the future.
Primary Outcome
Progression free survival as measured from the time of surgery until death or disease progression.
Conditions Studied
Interventions
- DRUG Gemcitabine
- PROCEDURE Cytoreductive Surgery
- DRUG Dacarbazine
- BEHAVIORAL Functional Assessment of Cancer Therapy (FACT) G questionnaire
- PROCEDURE Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) Scan
Study Locations (1)
California
- Stanford University - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2021-01-28 |
| Est. Completion | 2026-05 |
| Phase | Phase 2 |
What the registry record for NCT04727242 still lists
NCT04727242 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 44-participant average among 3 other Uterine Leiomyosarcoma trials with a reported enrollment target (61% lower).
The record links to 2 conditions, with Uterine Leiomyosarcoma appearing as the primary indexed condition, and to 5 interventions - of which Gemcitabine is the first listed.
NCT04727242 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04727242 about?
NCT04727242 is a clinical study titled "CytoreductiveSurgery & HIPEC w/Gemcitabine+Chemotherapy w/Dacarbazine in Uterine Leiomyosarcoma". The purpose of this study is to find out if giving a dose of heated chemotherapy in the abdomen immediately after surgery that is done to remove uterine leiomyosarcoma type of cancer will help lower the risk of the cancer coming back in the future.
What is the current status of trial NCT04727242?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2021-01-28. Estimated completion is 2026-05.
What conditions does trial NCT04727242 study?
This clinical trial studies the following conditions: Uterine Leiomyosarcoma, LMS - Leiomyosarcoma.
What interventions are being tested in trial NCT04727242?
The interventions under investigation include: Gemcitabine (DRUG), Cytoreductive Surgery (PROCEDURE), Dacarbazine (DRUG), Functional Assessment of Cancer Therapy (FACT) G questionnaire (BEHAVIORAL), Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) Scan (PROCEDURE).
Who is sponsoring clinical trial NCT04727242?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04727242 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Uterine Leiomyosarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI